Harrow Health, Inc. (HROW)

Market Cap	383.68M
Revenue (ttm)	130.19M
Net Income (ttm)	-24.41M
Shares Out	35.36M
EPS (ttm)	-0.75
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	346,231
Open	11.75
Previous Close	11.82
Day's Range	10.83 - 11.87
52-Week Range	7.60 - 28.25
Beta	0.50
Analysts	Strong Buy
Price Target	31.50 (+190.32%)
Earnings Date	May 9, 2024

About HROW

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic e...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Employees: 315
• Stock Exchange: NASDAQ
• Ticker Symbol: HROW

Financial Performance

In 2023, Harrow Health's revenue was $130.19 million, an increase of 46.95% compared to the previous year's $88.60 million. Losses were -$24.41 million, 73.3% more than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for HROW stock is "Strong Buy." The 12-month stock price forecast is $31.5, which is an increase of 190.32% from the latest price.

Price Target

$31.5

(190.32% upside)

Analyst Consensus: Strong Buy